08:23 AM EDT, 04/17/2026 (MT Newswires) -- Merck ( MRK ) said Friday that the European Commission has approved Enflonsia for the prevention of respiratory tract disease in newborns and infants.

The drug is designed to provide protection up to five months during their first respiratory tract disease, the company said.

The timing for availability of the drug will vary by country, the company said.

The approval was supported by a phase 2b/3 trial, the company said.